<p>Relmada Therapeutics, Inc.（纳斯达克代码：RLMD - 获取免费报告）首席财务官 Maged Shenouda 于 12 月 15 日星期一在一笔交易中购买了 11,665 股该股票。每股平均购买价格为 4.12 美元，总交易额为 48,059.80 美元。交易完成后，首席财务官在公司持有 800,000 股，估值约为 3,296,000 美元。这代表其持股增加了 1.48%。此次收购在向美国证券交易委员会（SEC）提交的法律文件中披露，该文件可通过 SEC 网站获取。</p>
<p>获取 <strong>Relmada Therapeutics</strong> 的提醒：</p>
<p>Maged Shenouda 最近还进行了以下交易：</p>
<ul>
<li>在 11 月 5 日星期三，Maged Shenouda 购买了 500,000 股 Relmada Therapeutics 的股票。每股平均购买价格为 2.20 美元，总价值为 1,100,000.00 美元。</li>
</ul>
<h2>Relmada Therapeutics 股票表现</h2>
<p>RLMD 股票在星期二开盘价为 4.71 美元。该公司的 50 日简单移动平均线为 3.21 美元，200 日简单移动平均线为 1.75 美元。Relmada Therapeutics, Inc.的 52 周最低价为 0.24 美元，52 周最高价为 5.12 美元。该股票的市值为 3.4511 亿美元，市盈率为-2.63，贝塔值为 0.74。</p>
<p>Relmada Therapeutics（纳斯达克代码：RLMD - 获取免费报告）最近于 11 月 13 日星期四公布了季度财报。公司报告每股收益（EPS）为（0.30）美元，低于市场共识预期的（0.04）美元，差距为（0.26）美元。卖方分析师预测 Relmada Therapeutics, Inc.在当前年度的每股收益为-2.73 美元。</p>
<h2>机构投资者对 Relmada Therapeutics 的看法</h2>
<p>几家对冲基金和其他机构投资者最近修改了对 RLMD 的持股。高盛集团在第一季度购买了 Relmada Therapeutics 的新头寸，价值 33,000 美元。AdvisorShares Investments LLC 在第二季度将其在 Relmada Therapeutics 的持股增加了 43.4%。AdvisorShares Investments LLC 现在持有 396,514 股该公司的股票，价值 238,000 美元，在上个季度购买了额外的 120,000 股。Marshall Wace LLP 在第二季度收购了 Relmada Therapeutics 的新股份，价值 93,000 美元。Corient Private Wealth LLC 在第二季度收购了 Relmada Therapeutics 的新股份，价值约 120,000 美元。最后，Two Sigma Investments LP 在第三季度将其在 Relmada Therapeutics 的股份增加了 82.0%。Two Sigma Investments LP 现在持有 173,614 股该公司的股票，价值 349,000 美元，在此期间又收购了 78,197 股。机构投资者和对冲基金持有该公司 45.24% 的股票。</p>
<h2>华尔街分析师的看法</h2>
<p>几家券商最近对 RLMD 发表了评论。Weiss Ratings 在 10 月 31 日星期五的研究报告中重申了对 Relmada Therapeutics 股票的 “卖出（e+）” 评级。瑞穗证券在 11 月 19 日星期三将 Relmada Therapeutics 的股票评级从 “中性” 上调至 “跑赢大盘”，并将其目标价格从 1.00 美元提高至 10.00 美元。最后，Wall Street Zen 在 10 月 11 日星期六的研究报告中将 Relmada Therapeutics 的评级上调至 “持有”。一位研究分析师给予该股票 “买入” 评级，另一位则给予该公司股票 “卖出” 评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “持有”，共识目标价格为 10.00 美元。</p>
<p><strong>查看我们最新的 RLMD 股票分析</strong></p>
<h2>关于 Relmada Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Relmada Therapeutics, Inc.是一家临床阶段的生物技术公司，专注于开发各种产品以治疗美国的中枢神经系统疾病（CNS）及其他疾病。其主要产品候选药物是 Esmethadone（d-美沙酮，右美沙酮和 REL-1017），这是一种 N-甲基-D-天冬氨酸受体拮抗剂，目前正在进行针对重度抑郁症的辅助或单药治疗的第三阶段临床试验。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 Relmada Therapeutics 更好</li>
<li>现在购买的三只最佳金融科技股票</li>
<li>三家医疗巨头刚刚提高了股息——谁支付得最多</li>
<li>最佳股票低于 5.00 美元</li>
<li>低调的 Evergy Energy：您收入投资组合所需的 AI 助力</li>
<li>在 52 周高点盈利交易股票</li>
<li>辉瑞加大对减肥药物的投资</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkxNRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkxNRA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元于 Relmada Therapeutics 吗？</h2>
<p>在您考虑 Relmada Therapeutics 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Relmada Therapeutics 并不在名单上。</p>
<p>虽然 Relmada Therapeutics 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

RLMD

<p>Relmada Therapeutics 首席财务官 Maged Shenouda 以每股 4.12 美元的价格购买了 11,665 股，总计 48,059.80 美元。交易后，他持有 800,000 股，价值 3,296,000 美元，增幅为 1.48%。该交易已在 SEC 文件中披露。Shenouda 还在 11 月 5 日以每股 2.20 美元的价格购买了 500,000 股，总计 1,100,000 美元。RLMD 股票在周二开盘价为 4.71 美元。公司报告第三季度每股亏损 0.30 美元。机构投资者持有 RLMD 45.24% 的股份。分析师对该股票的评级褒贬不一</p>

<p>Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) CFO Maged Shenouda acquired 11,665 shares of the stock in a transaction on Monday, December 15th. The shares were purchased at an average price of $4.12 per share, for a total transaction of $48,059.80. Following the completion of the transaction, the chief financial officer owned 800,000 shares in the company, valued at approximately $3,296,000. This represents a 1.48% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website.</p>
<div class="lb-trans"><p>Relmada Therapeutics, Inc.（纳斯达克代码：RLMD - 获取免费报告）首席财务官 Maged Shenouda 于 12 月 15 日星期一在一笔交易中购买了 11,665 股该股票。每股平均购买价格为 4.12 美元，总交易额为 48,059.80 美元。交易完成后，首席财务官在公司持有 800,000 股，估值约为 3,296,000 美元。这代表其持股增加了 1.48%。此次收购在向美国证券交易委员会（SEC）提交的法律文件中披露，该文件可通过 SEC 网站获取。</p>
</div><p>Get <strong>Relmada Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Relmada Therapeutics</strong> 的提醒：</p>
</div><p>Maged Shenouda also recently made the following trade(s):</p>
<div class="lb-trans"><p>Maged Shenouda 最近还进行了以下交易：</p>
</div><ul>
<li>On Wednesday, November 5th, Maged Shenouda acquired 500,000 shares of Relmada Therapeutics stock. The shares were acquired at an average price of $2.20 per share, with a total value of $1,100,000.00.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 11 月 5 日星期三，Maged Shenouda 购买了 500,000 股 Relmada Therapeutics 的股票。每股平均购买价格为 2.20 美元，总价值为 1,100,000.00 美元。</li>
</ul>
</div><h2>Relmada Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Relmada Therapeutics 股票表现</h2>
</div><p>RLMD stock opened at $4.71 on Tuesday. The firm has a 50 day simple moving average of $3.21 and a 200 day simple moving average of $1.75. Relmada Therapeutics, Inc. has a 52 week low of $0.24 and a 52 week high of $5.12. The stock has a market cap of $345.11 million, a P/E ratio of -2.63 and a beta of 0.74.</p>
<div class="lb-trans"><p>RLMD 股票在星期二开盘价为 4.71 美元。该公司的 50 日简单移动平均线为 3.21 美元，200 日简单移动平均线为 1.75 美元。Relmada Therapeutics, Inc.的 52 周最低价为 0.24 美元，52 周最高价为 5.12 美元。该股票的市值为 3.4511 亿美元，市盈率为-2.63，贝塔值为 0.74。</p>
</div><p>Relmada Therapeutics (NASDAQ:RLMD - Get Free Report) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.26). Sell-side analysts predict that Relmada Therapeutics, Inc. will post -2.73 EPS for the current year.</p>
<div class="lb-trans"><p>Relmada Therapeutics（纳斯达克代码：RLMD - 获取免费报告）最近于 11 月 13 日星期四公布了季度财报。公司报告每股收益（EPS）为（0.30）美元，低于市场共识预期的（0.04）美元，差距为（0.26）美元。卖方分析师预测 Relmada Therapeutics, Inc.在当前年度的每股收益为-2.73 美元。</p>
</div><h2>Institutional Investors Weigh In On Relmada Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Relmada Therapeutics 的看法</h2>
</div><p>Several hedge funds and other institutional investors have recently modified their holdings of RLMD. Goldman Sachs Group Inc. bought a new position in Relmada Therapeutics during the first quarter worth $33,000. AdvisorShares Investments LLC grew its position in Relmada Therapeutics by 43.4% in the 2nd quarter. AdvisorShares Investments LLC now owns 396,514 shares of the company's stock worth $238,000 after purchasing an additional 120,000 shares during the last quarter. Marshall Wace LLP acquired a new stake in Relmada Therapeutics in the 2nd quarter worth $93,000. Corient Private Wealth LLC acquired a new stake in Relmada Therapeutics during the second quarter worth about $120,000. Finally, Two Sigma Investments LP increased its stake in Relmada Therapeutics by 82.0% during the third quarter. Two Sigma Investments LP now owns 173,614 shares of the company's stock valued at $349,000 after acquiring an additional 78,197 shares during the period. Institutional investors and hedge funds own 45.24% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近修改了对 RLMD 的持股。高盛集团在第一季度购买了 Relmada Therapeutics 的新头寸，价值 33,000 美元。AdvisorShares Investments LLC 在第二季度将其在 Relmada Therapeutics 的持股增加了 43.4%。AdvisorShares Investments LLC 现在持有 396,514 股该公司的股票，价值 238,000 美元，在上个季度购买了额外的 120,000 股。Marshall Wace LLP 在第二季度收购了 Relmada Therapeutics 的新股份，价值 93,000 美元。Corient Private Wealth LLC 在第二季度收购了 Relmada Therapeutics 的新股份，价值约 120,000 美元。最后，Two Sigma Investments LP 在第三季度将其在 Relmada Therapeutics 的股份增加了 82.0%。Two Sigma Investments LP 现在持有 173,614 股该公司的股票，价值 349,000 美元，在此期间又收购了 78,197 股。机构投资者和对冲基金持有该公司 45.24% 的股票。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师的看法</h2>
</div><p>Several brokerages have recently commented on RLMD. Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of Relmada Therapeutics in a research note on Friday, October 31st. Mizuho raised shares of Relmada Therapeutics from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and increased their target price for the stock from $1.00 to $10.00 in a research report on Wednesday, November 19th. Finally, Wall Street Zen raised Relmada Therapeutics to a &#34;hold&#34; rating in a research report on Saturday, October 11th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of &#34;Hold&#34; and a consensus target price of $10.00.</p>
<div class="lb-trans"><p>几家券商最近对 RLMD 发表了评论。Weiss Ratings 在 10 月 31 日星期五的研究报告中重申了对 Relmada Therapeutics 股票的 “卖出（e+）” 评级。瑞穗证券在 11 月 19 日星期三将 Relmada Therapeutics 的股票评级从 “中性” 上调至 “跑赢大盘”，并将其目标价格从 1.00 美元提高至 10.00 美元。最后，Wall Street Zen 在 10 月 11 日星期六的研究报告中将 Relmada Therapeutics 的评级上调至 “持有”。一位研究分析师给予该股票 “买入” 评级，另一位则给予该公司股票 “卖出” 评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “持有”，共识目标价格为 10.00 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on RLMD</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 RLMD 股票分析</strong></p>
</div><h2>About Relmada Therapeutics</h2>
<div class="lb-trans"><h2>关于 Relmada Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.</p>
<div class="lb-trans"><p>Relmada Therapeutics, Inc.是一家临床阶段的生物技术公司，专注于开发各种产品以治疗美国的中枢神经系统疾病（CNS）及其他疾病。其主要产品候选药物是 Esmethadone（d-美沙酮，右美沙酮和 REL-1017），这是一种 N-甲基-D-天冬氨酸受体拮抗剂，目前正在进行针对重度抑郁症的辅助或单药治疗的第三阶段临床试验。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Relmada Therapeutics</li>
<li>The 3 Best Fintech Stocks to Buy Now</li>
<li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li>
<li>Best Stocks Under $5.00</li>
<li>Unassuming Evergy Energy: The AI Boost Your Income Portfolio Needs</li>
<li>Profitably Trade Stocks at 52-Week Highs</li>
<li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Relmada Therapeutics 更好</li>
<li>现在购买的三只最佳金融科技股票</li>
<li>三家医疗巨头刚刚提高了股息——谁支付得最多</li>
<li>最佳股票低于 5.00 美元</li>
<li>低调的 Evergy Energy：您收入投资组合所需的 AI 助力</li>
<li>在 52 周高点盈利交易股票</li>
<li>辉瑞加大对减肥药物的投资</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkxNRA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=RLMD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Relmada Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元于 Relmada Therapeutics 吗？</h2>
</div><p>Before you consider Relmada Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Relmada Therapeutics 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Relmada Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Relmada Therapeutics 并不在名单上。</p>
</div><p>While Relmada Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Relmada Therapeutics 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Relmada Therapeutics (NASDAQ:RLMD) 的首席财务官购入了价值 48,059.80 美元的股票